. N. Effect of SGLT2 inhibitor (Empagliflozin) on HbA1c in most Prevalent Age Group of Type 2 Diabetic Patients. Int J Pathol. 2023;20(4):178-181. Accessed May 7, 2024. https://jpathology.com/index.php/OJS/article/view/802